Associate Professor of Medical Oncology
Hassan II University Hospital, Morocco
Karima Oualla, MD, MSc
Associate Professor of Medical Oncology, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fez, Morocco
Referent on GU cancers Hassan II University Hospital-Morocco
Council member of the Global Society of Rare Genitourinary Tumors (GSRGT)
Joint committee International Bladder Cancer Group IBCG-GSRGT
World Bladder Cancer Patients Coallition Scientific Advisory Board
Short biography:
Dr Oualla completed her medical training at University Sidi Mohamed Ben Abdellah prior to practicing as a Medical Oncologist at Hassan II University Hospital. She joined Institut Jules Bordet in Brussels, Belgium, as an assistant doctor (2012–2013). Dr Oualla holds a certificate of specialization in Medical Oncology from the Université Libre de Bruxelles, and completed a 3-year postgraduate course in Medical Oncology (European Organisation for Research and Treatment of Cancer [EORTC]-affiliated National Belgian Programme for Inter-University Faculty).
Dr Oualla was awarded a fellowship by the European Society of Medical Oncology (ESMO) on Onco-Urology at the Istituto Nazionale dei Tumori, in Milan, Italy where she worked in Onco-Urology Unit. In 2015, she joined the Cancer Prevention and Control Research Training Programme at the Department of Public Health in the University of South Florida, in Tampa, FL, USA, funded by the National Institutes of Health (NIH) Fogarty International Center, Bethesda, MD, USA, and Moffitt Cancer Center, Tampa (2015–2016). She completed a master’s degree in Science at Ulm University,Germany in 2020.
Dr Oualla was designated as an ambassador of the European School of Oncology for the years 2023 and 2024.
Dr Oualla serves on the leadership Council of the Global Society of Rare Genitourinary Tumors (GSRGT), and the scientific committee of the International Bladder Cancer Group (IBCG) and the Specialty editor on GU at ESMO Open.
B2B-01: SOA: Advances in Perioperative Therapy for Muscle-invasive Bladder Cancer
Friday, October 31, 2025
10:55 - 11:10 GMT+0
B2B-01: Case-Based Panel Discussion: Systemic therapy in metastatic bladder cancer
Friday, October 31, 2025
11:10 - 11:45 GMT+0
B2B-02: Welcome and Introductions
Friday, October 31, 2025
12:00 - 12:05 GMT+0
B2B-02: Case-Based Panel Discussion
Friday, October 31, 2025
12:25 - 12:40 GMT+0
Friday, October 31, 2025
12:00 - 12:45 GMT+0
B2B-03: Panel Discussion: Systemic therapy combination in metastatic RCC
Friday, October 31, 2025
13:40 - 14:10 GMT+0
HT-04: Hot Topics: Testicular Cancer - Improving Survivorship and Survival
Friday, October 31, 2025
15:15 - 16:45 GMT+0